Reversal of adynamic bone disease by lowering of dialysate calcium

Kidney International

Volumn 70, Issue 5, 2006, Pages 931-937

  Haris, A ^a   Sherrard, D J ^b   Hercz, G ^c  

^a St Margit Hospital   (Hungary)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

Adynamic bone disease; Peritoneal dialysis; Renal osteodystrophy

Indexed keywords

DIANEAL; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

BIOPSY; BONE AND BONES; BONE DENSITY; CALCIUM; DIALYSIS SOLUTIONS; FEMALE; HUMANS; HYPERCALCEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOGENESIS; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; RENAL OSTEODYSTROPHY;

EID: 33747821066     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001666     Document Type: Article

References (40)

1. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996; 11(Suppl 3): 111-120.
2. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442.
3. Pei Y, Hercz G. Low turnover bone disease in dialysis patients. Semin Dial 1996; 9: 327-331.
4. Pei Y, Hercz G. Approach to the patient with suspected renal osteodystrophy, including indications for bone biopsy. In: Bushinsky DA (ed). Renal Osteodystrophy. Lippincott-Raven Publishers: Philadelphia, 1998: 265-282.
5. Ballanti P, Wedard BM, Bonucci E. Frequency of adynamic bone disease and aluminium storage in Italian uremic patients - retrospective analysis of 1429 iliac crest biopsies. Nephrol Dial Transplant 1996; 11: 663-667.
6. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
7. Sánchez MC, Bajo MA, Selgas R et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000; 36: 953-961.
8. Hernandez D, Concepcion MT, Lorenzo V et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9: 517-523.
9. Mucsi I, Hercz G. Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 1997; 7: 356-361.
10. Hutchison AJ, Moore PR. Low turnover bone disease. Periton Dial Int 1996; 16(Suppl 1): 295-299.
11. London GM, Pannier B, Marchais SJ, Guerin A. Calcifications of the aortic valve in the dialysed patient. J Am Soc Nephrol 2000; 11: 778-783.
12. K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S12-S28.
13. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int 1993; 44: 860-866.
14. Goodman W, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166.
15. Weinreich T. Prevention of renal osteodystrophy in peritoneal dialysis. Kidney Int 1998; 54: 2226-2233.
16. Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens 2000; 9: 363-367.
17. Pei Y, Hercz G, Greenwood C et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159-164.
18. Malluche HH, Monier-Faugere M. Risk of adynamic bone disease in dialysed patients. Kidney Int 1992; 42(Suppl 38): S62-S67.
19. Navarro JF, Mora C, Macia M, Garcia J. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Periton Dial Int 1999; 19: 455-461.
20. Charhon SA, Berland YF, Olmer MJ et al. Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients. Kidney Int 1985; 27: 426-435.
21. Bender FH, Bernardini J, Piraino B. Calcium mass transfer with dialysate containing 1.25 and 1.75 mM calcium in peritoneal dialysis patients. Am J Kidney Dis 1992; 20: 367-371.
22. Armstrong A, Beer J, Noonan K, Cunningham J. Reduced calcium dialysate in CAPD patients: efficacy and limitations. Nephrol Dial Transplant 1997; 12: 1223-1228.
23. Chagnac A, Ori Y, Weinstein T et al. Calcium balance during pulse alfacalcidiol therapy for secondary hyperparathyroidism in CAPD patients treated with 1.0 and 1.25 mM dialysate calcium. Am J Kidney Dis 1999; 33: 82-86.
24. Kurz P, Monier-Faugere M, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
25. Chagnac A, Ori Y, Weinstein T et al. Hypercalcemia during pulse vitamin D3 therapy in CAPD patients treated with low calcium dialysate: the role of the decreasing serum parathyroid hormone level. J Am Soc Nephrol 1997; 8: 1579-1586.
26. Cannata-Andia JB. Pathogenesis, prevention and management of low-bone turnover. Nephrol Dial Transplant 2000; 15(Suppl 5): 15-17.
27. Salusky IB, Goodman WG. Managing phosphate retention: is a change necessary? Nephrol Dial Transplant 2000; 15: 1738-1742.
28. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
29. Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 13: 159-168.
30. Towler DA. Vascular calcification in ESRD: another cloud appears in the perfect storm - but highlights a silver lining? Editorial. Kidney Int 2004; 66: 2467-2468.
31. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
32. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.
33. Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1 mmol/l) in CAPD: effects on bone mineral metabolism. Periton Dial Int 1996; 16: 260-268.
34. Buijsen CGM, Struijk DG, Huijgen HJ et al. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Periton Dial Int 1996; 16: 497-505.
35. Duncan R, Cochrane T, Bhalla C et al. Low calcium dialysate and hyperparathyroidism. Periton Dial Int 1996; 16(Suppl 1): S499-S502.
36. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104-115.
37. Wang M, Hercz G, Sherrard DJ et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844.
38. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
39. Avins AL. Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics 1998; 24: 401-408.
40. Edwards SJL, Braunholtz DA. Can unequal be more fair? A response to Andrew Avins. J Med Ethics 2000; 26: 179-182.